U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07795125) titled 'Rimegepant For Endometriosis Pain' on Aug. 26.
Brief Summary: The purpose of this study is to evaluate the efficacy of rimegepant 75 mg versus placebo in reducing endometriosis-associated pain (EAP) in women with moderate-to-severe pain and histologically confirmed endometriosis.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Endometriosis
Endometriosis-related Pain
Intervention:
DRUG: Rimegepant 75 MG
Rimegepant 75 mg oral capsule administered every other day for 12 weeks
DRUG: Placebo
Matching placebo oral capsule administered every other day for 12 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor...